More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells

Si-yang Zhang¹, Lin-ping Hui², Chun-yan Li¹, Jian Gao¹, Ze-shi Cui*¹ and Xue-shan Qiu³

Abstract

Background: Brain-derived neurotrophic factor (BDNF) has been reported to promote tumorigenesis and progression in several human malignancies. The purpose of this study was to explore the function of BDNF in lung squamous cell carcinoma (SCC) and adenocarcinoma (ADC).

Methods: The expression of BDNF was examined in 110 samples of lung SCC and ADC by immunohistochemistry. The protein level of BDNF was examined in 25 lung SCC or ADC samples and paired non-tumors by western blot. BDNF expression was also evaluated in human bronchial epithelial cells (HBE) and 4 lung cancer cell lines using western blot. Three BDNF mRNA variants containing exons IV, VI and IX were evaluated in HBE, two SCC (SK, LK2) and two ADC (A549, LTE) cell lines by RT-PCR. The expression and secretion of BDNF were also determined in cells using western blot and ELISA. Then the shRNA specific for BDNF was transfected into LK2 or A549 cells to further elucidate the BDNF knockdown on cell proliferation, apoptosis and invasion, which were confirmed by MTT, flow cytometry and transwell examinations.

Results: 71.8 % (79 out of 110) of lung SCC and ADC samples were detected positive BDNF, and high expression of BDNF was significantly correlated with histological type and T stage. Compared with non-tumorous counterparts, BDNF was apparently overexpressed in SCC and ADC tissues. In cell studies, the extensive expression and secretion of BDNF were demonstrated in lung cancer cells compared with HBE cells. Interestingly, the expressions of BDNF mRNA variant IV and VI were identical in all cells examined. However, more expression of BDNF mRNA variant IX was found in SK and LK2 cells. The apoptotic cells were increased, and the cell proliferation and invasion were both attenuated once the expression of BDNF was inhibited. When retreated by rhBDNF, BDNF knockdown cells showed less apoptotic or more proliferative and invasive.

Conclusions: Our data show that BDNF probably facilitates the tumorigenesis of lung SCC and ADC. The expression of BDNF mRNA variant IX is probably more helpful to the upregulation of BDNF in SCC, and intervening the production of BDNF could be a possible strategy to lung cancer therapy.

Keywords: BDNF, Expression, Knockdown, Lung SCC, ADC
Background
Lung cancer is a common and serious malignant tumor worldwide, and the incidence and mortality of lung cancer are increasing every year. Lung SCC and ADC are the primary histological classification of lung cancer and included in this study. The outcome of patients with lung cancer mainly depends on tumor development and evolution, which are closely associated with the expression of tumor related genes. More research should be performed to identify the regulatory function of those genes.

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family. BDNF plays an important role in the development and regeneration of the neurons. Binding of BDNF to its major receptor, tropomyosin-related receptor kinase B (TrkB) with high affinity and specificity [1], leads to the activations of various downstream signalings, including PI3K/AKT, RAS/ERK, PLC/PKC, AMPK/ACC and JAK/STAT pathways [2]. BDNF and TrkB have been reported to promote tumorigenesis and progression in several human malignancies such as neuroblastoma [3], breast [4], lung [5], prostate [6], and colon cancer [7]. Studies have shown that BDNF/TrkB signaling was involved in proliferative [8] or invasive properties [9]. These findings indicated that BDNF/TrkB signaling was closely associated with tumor progression [10], and it has emerged as a potential therapeutic target [11].

Researches focused on the function of BDNF/TrkB in lung cancer were also performed in recent years. Ricci A and his colleagues recognized the importance of neurotrophins and receptors family for human lung cancer [12]. It has been reported that the expression of TrkB and BDNF was associated with poor prognosis in non-small cell lung cancer [13] and TrkB/BDNF signaling pathway could be a therapeutic target for pulmonary large cell neuroendocrine carcinoma [14]. We previously demonstrated the involvement of the BDNF/TrkB pathway in the invasion of A549 cells [15].

However, despite the considerable amount of studies on BDNF have been reported in human cancer, here we investigated the function of BDNF in lung SCC and ADC. We reported here that the overexpression of BDNF was common in SCC and ADC, particularly correlated with histological type and T stage. We also reported that the expression and secretion of BDNF were more extensive in lung cancer cells. Moreover, the BDNF mRNA variant containing exon IX was important to the higher expression in SCC cells, and BDNF was critical to the proliferation and invasion of lung cancer cells.

Methods
Lung cancer samples
110 cases of lung SCC and ADC samples were all from the Pathology Department in China Medical University. The ethical approval was given by the Medical Research Ethics Committee of China Medical University. All participants were provided the written informed consent before enrolment in this study and the agreements were obtained. The enrolled cases did not receive any chemotherapy or radiation therapy before curative surgical resection. Formalin-fixed paraffin-embedded sections of tumor were stained with hematoxylin and eosin (HE), and diagnosed according to the guidelines of classification of lung and pleural tumors (2004) and the TNM staging system (1997) of WHO by two senior pathologists. The histological type, differentiation, stage and lymph node metastasis were determined accordingly and summarized in Table 1.

Immunohistochemistry
110 paraffin sections of lung SCC and ADC were deparaffinized and rehydrated routinely. The sections were heated in 0.1 mol/L Tris–HCl at pH10 in an autoclave sterilizer for 1 min for the recovery of antigen. The sections were then incubated with 3 % H2O2 to eliminate endogenous peroxidase, followed by 5 % goat serum to avoid unspecific binding of antibody at 37 °C for 1 h. The sections were then incubated with primary mouse monoclonal antibody specific for BDNF (1:100 dilution, Abcam) overnight at 4 °C. The next day, sections were incubated with goat anti-mouse IgG and streptavidin-peroxidase (SP) complex at 37 °C for 40 min (SP kit, Maxim, China), and then developed with 3,3′-diaminobenzidine (DAB). Neuroblastoma was used as positive control for BDNF, and nonimmune goat IgG instead of BDNF antibody was used as negative control. Two senior pathologists assessed the immunostained sections separately. The distinguishing brown particles in cytoplasm were regarded as BDNF-positive. The intensity of BDNF immunostaining (0 = negative, 1 = weak, 2 = intense) and the percentage of positive tumor cells (≤50 % = 1, >50 % = 2) were evaluated in at least 5 high power fields (×400 magnification). The scores of each tumor section were multiplied to generate a final score of 0, 1, 2 or 4, and the samples were finally defined as high expression: score >2; or low expression: score ≤2 (including negative: score 0).

Cells culture and transfection
Human bronchial epithelial cells (HBE), lung SCC cells (SK-MES-1, LK2) and ADC cells (A549, LTE) were cryopreserved in our department. HBE, A549 and LTE cells were cultured in RPMI1640 (Gibco, USA), and SK, LK2 cells were cultured using DMEM (Gibco, USA), supplemented with 10 % fetal bovine serum (FBS), in an incubator at 37 °C with 5 % CO2. LK2 and A549 cells were selected to perform the establishment of stable cell strain with BDNF knockdown for their better condition and vitality. They (50-60 % confluence) were transfected with either BDNF-shRNA or scrambled control (Genechem,
China) using Lipofectamin 2000 (Invitrogen, USA), according to the manufacturer’s guidelines. The qualified cell clones were screened by G418, and the decreased expression of BDNF was confirmed by western blot. When indicated, those transfected cells were retreated with recombinant human BDNF (rhBDNF, 100 ng/mL, Peprotech, USA). Cells were used for proteins extraction or cell biological assays as described below. The experiments for cells were performed in triplicates.

**Western blot**

25 cases of fresh SCC (10) and ADC (15) were obtained from the Pathology Department. Tissues or cells were washed with ice-cold phosphate buffer saline (PBS) and lysed in RIPA lysis buffer containing protease inhibitor (Roche, USA). The homogenate was centrifuged at 15,000 g at 4 °C for 30 min. The supernatant was collected and protein content was quantified by the method of bicinchoninic acid (BCA) assay (Pierce). 60 μg of protein sample was loaded in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane. 5 % bovine serum albumin (BSA) was used to block unspecific binding of antibodies to membrane. Then the primary antibodies containing mouse monoclonal anti-BDNF (1:200, Abcam, USA) or rabbit polyclonal anti-BDNF (1:200, Sangon, China) and anti-β-actin (1:1000, Santa Cruz, USA) were incubated with membranes at 4 °C over night. The membranes were then incubated with goat anti-mouse or rabbit IgG (1:2000, ZhongShan, China) at 37 °C for 2 h. The specific protein bands were visualized using the enhanced chemiluminescence (ECL) method (TranGen Biotech, China), using the DNR Imaging System. The Image-Pro Plus 6.0 software was used to perform semi-quantitative analysis of the optical density of each band. The ratio between the optical density of BDNF and β-actin of the same sample was used to indicate the relative level of BDNF expression.

**ELISA**

Human BDNF Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) was used to measure the protein concentration of BDNF in the supernatant collected by centrifugation from cultured cells for 24 or 48 h. BDNF secretion was evaluated according to the manufacturer’s instructions. In general, 50 μL of sample or standard was mixed with 100 μL assay diluent and added to the microplate wells, incubating at room temperature for 2 h. The mixture was incubated at room temperature for another 1 h after adding 100 μL of BDNF conjugate. The development reaction was performed with 200 μL of substrate solution after several washes. Then the absorbance value was shown by a microplate reader at 450 nm, with a calibration wavelength of 570 nm.

**Reverse transcription polymerase chain reaction**

Total RNA of cells was extracted using Trizol (Invitrogen, USA). cDNA was produced by reverse transcription reaction of 5 μg total RNA using GoScript Reverse Transcription System (Promega, USA). The primer sequences used in this study were listed in Table 2. The lengths of the PCR products using the reverse primer hBDNF_IXbAS in combination with the following forward primers were hBDNF_IVS, 412 bp; hBDNF_VIS, 494, 387, and 369 bp;

---

**Table 1** Statistical analysis on the correlations between BDNF expression by immunohistochemical staining in 110 lung cancer samples and the clinicopathological parameters

| Clinicopathological Characteristics | Cases (n = 110) | Low expression (n = 49) | High expression (n = 61) | p-value |
|------------------------------------|----------------|------------------------|-------------------------|---------|
| Histological type                  |                |                        |                         |         |
| Squamous cell carcinoma            | 53             | 20                     | 33                      | 0.017   |
| Adenocarcinoma                     | 57             | 29                     | 18                      |         |
| Grade                              |                |                        |                         |         |
| well-moderate                      | 76             | 31                     | 45                      | 0.236   |
| poor                               | 34             | 18                     | 16                      |         |
| Stage                              |                |                        |                         |         |
| I-II                               | 72             | 36                     | 36                      | 0.113   |
| III                                | 38             | 13                     | 25                      |         |
| Tumor size and extension           |                |                        |                         |         |
| T1-T2                              | 75             | 39                     | 36                      | 0.021   |
| T3                                 | 35             | 10                     | 25                      |         |
| Lymph node metastasis              |                |                        |                         |         |
| No                                 | 68             | 30                     | 38                      | 0.532   |
| Yes                                | 42             | 19                     | 23                      |         |

---

Zhang et al. BMC Cancer (2016) 16:171 Page 3 of 11
Table 2 The primers of 3 BDNF mRNA variants and β-actin used in this study

| mRNA Variant | Forward Sequence | Reverse Sequence | Annealing Temperature |
|--------------|-----------------|-----------------|-----------------------|
| hBDNF_IVS    | 5′-GCTGAGAAGAAGAGGAGATACA-3′ | 5′-GTCCTCATCAAAGCTCCTTATC-3′ | 61.8 °C                |
| hBDNF_VIS    | 5′-GGCTTTAATGAGACCACCCG-3′ | 5′-GTCCTCATCAAAGCTCCTTATC-3′ | 63.3 °C                |
| hBDNF_IXS    | 5′-TTTTGTGACACGATAGCAG-3′ | 5′-GTCCTCATCAAAGCTCCTTATC-3′ | 60.6 °C                |
| β-actin      | 5′-TGAGTCCTCCTTGGAAATCTCAG-3′ | 5′-TAGCAACGTATGCGCTGGA-3′ | 55 °C                 |

and hBDNF_IXS, 597 and 363 bp, respectively (as described by Prof. Pruunsild) [16]. PCR conditions were set as follows: initial denaturation at 94 °C for 2 min; 35 cycles of denaturation at 94 °C for 30s; annealing at appropriate temperature listed in the Table 1 for 30s; elongation at 72 °C for 30s; final elongation at 72 °C for 5 min. The PCR conditions for β-actin were similar to that for BDNF mRNA variants, except for annealing at 55 °C and 30 cycles. The specific bands were visualized using the ChemiImager 5500 (Alpha Innotech, USA), and the Image-Pro Plus 6.0 software was used for the semi-quantitative analysis of the optical density of each band.

CCK-8 assay

The cell proliferation was evaluated using CCK-8 (DOJINDO, Japan) assay, which was lasted for 5 days. Cells were digested, counted, and adjusted to $1 \times 10^5/100 \mu L$, and seeded in five 96-well plates simultaneously. Every day, a random plate was selected for the measurements of absorbance, and cells in other plates were cultured for the rest of days. The absorbance of each well was measured in a microplate reader (SpectraMax Plus 384, USA) at 450 nm at 4 h after 10 μL CCK-8 was added. The average absorbance (Y-axis) and time (X-axis) were applied to draw the cell growth curves. Data indicated are mean value of three individual wells.

Cell apoptosis assay

The Annexin V-FITC (fluorescein isothiocyanate) apoptosis detection kit (BD Biosciences, USA) was used to monitor cell apoptosis by flow cytometry, according to the manufacturer’s protocol. Cells were rinsed twice using ice-cold PBS and resuspended in 1 x binding buffer (1 x $10^6$/mL). 100 μL (1 x $10^5$) cells were gently mixed with 5 μL PI and 5 μL Annexin V-FITC, and incubated for 15 min at room temperature in dark. Cells were supplemented with another 400 μL 1 x binding buffer, and examined in a flow cytometer. Data are representative of three individual tests.

Cell invasion analysis

The 24-well Transwell chamber (Costar, USA) was used to perform cell invasion assay. Cells were digested, counted and adjusted to $1 \times 10^5$, and seeded in the upper chamber with an 8 μm pore size insert in a 24-well plate. The inserts were precoated with Matrigel (1:6 dilution, BD Biosciences) and cells were cultured in medium containing 1 % FBS. They were driven to invade Matrigel and migrate towards medium containing rhBDNF (100 ng/mL) or 10 % FBS in the bottom chamber for 24 h. After removing the detained cells on the upper surface of membrane with a cotton tip, the migratory cells on the under surface were fixed using 4 % paraformaldehyde and stained with hematoxylin. The number of invaded cells was counted in 5 randomly selected fields under a microscope of 200× power. Data expressed are mean value of three individual wells.

Statistical analysis

SPSS 13.0 statistical analysis software was used to perform data statistics. $\chi^2$-test was applied to evaluate the correlations of BDNF expression and clinicopathological parameters for the immunohistochemical results. The $t$-test was used to evaluate the difference of BDNF expression between tumors and non-tumor counterparts. One-way ANOVA was used to evaluate the differences between variously treated cells. All data were shown as mean ± SD and results were regarded statistically significant when the $p$ value <0.05.

Results

BDNF expression in specimens of lung SCC and ADC by Immunohistochemistry

Weak expression of BDNF was shown in the cytoplasm of bronchial epithelial cells (Fig. 1a), and no expression was found in alveolar epithelium (Fig. 1d). BDNF immunostaining was observed in the cytoplasm of cancer cells. Positive BDNF was found in 79 (71.8 %) neoplastic sections. We considered that 61 (55.5 %) cases were high expression (scores >2) and 49 cases (44.5 %) were low expression (scores ≤2), as elaborated in Methods. BDNF
was reported to be correlated with tumor growth, inva-
siveness and metastasis, so the association between BDNF
expression and clinicopathological characteristics was
analyzed statistically, as shown in Table 1. BDNF im-
munostaining was stronger in tumors of SCC (vs. ADC,
\( p = 0.017 \)) and T3 (vs. T1-T2, \( p = 0.021 \)). And no signifi-
cant difference of BDNF expression was found between
tumors with various differentiation (well-moderate vs
poor, \( p = 0.236 \)), stage I-II (vs. III, \( p = 0.113 \)) and lymph
node status (metastasis vs no metastasis, \( p = 0.532 \)).

**BDNF expression in 25 cases of tumor and paired non-tumor
by western blot**

Western blot analysis was used to detect BDNF expres-
sion in 10 SCC and 15 ADC cases of lung cancer and
non-tumorous tissue distant from the primary tumor of
the same case. The overexpression of BDNF was found
in 20 tumor samples in comparison with the non-tumor
counterparts (\( p = 0.000 \)). The specific bands for BDNF of
eight samples are shown in Fig. 2a, and the relative op-
tical density of the tumor (T) and non-tumor (N) tissues
of the same patient was measured and expressed graphi-
cally (Fig. 2b).

**BDNF expression in HBE and four lung cancer cell lines by
western blot**

The expression of BDNF was also examined in HBE,
two lung SCC (SK, LK2) and two ADC (A549, LTE) cell
lines using western blot. We showed that the expression
of BDNF represented by the specific bands of 28 kDa
was almost undetectable in HBE cells. However, the IOD
indicative of BDNF protein level was excessively high in
lung cancer cells (Fig. 3). Statistical analysis confirmed
that SK and LK2 cells expressed more BDNF than A549
and LTE cells (\( p = 0.000 \)).

**The secretory BDNF in supernatants of cells by ELISA**

BDNF is a secretory cytokine, which is prepared by
tumor cells and promotes growth and survival of them-
selves [17]. In the present study, BDNF secreted by HBE,
SK, LK2, A549 and LTE cells was measured by ELISA
assays. Our results showed that BDNF in supernatant
of HBE and A549 cells at 24 or 48 h were not detected.
BDNF in supernatant of LTE cells was undetected at 24 h, which was 30.5 ± 18.0 pg/mL at 48 h. The concentration of BDNF in supernatant of SK and LK2 cells were 38.3 ± 15.5 and 29.0 ± 11.6 pg/mL at 24 h, and 150.5 ± 54.0 and 212.0 ± 88.0 pg/mL at 48 h, respectively. These results indicated that more BDNF was produced by SK and LK2 cells.

The expression of BDNF mRNA variants in cells by RT-PCR
BDNF has multiple alternative splicing variants and plays diverse biological functions in mammals, including neuronal survival, cell differentiation and tumor development. The multiple BDNF alternative splicing variants are formed to achieve precise temporal and spatial expression of functional BDNF. The expressions of BDNF mRNA variants containing exons IV, VI and IX were selected according to previous reports [16], and investigated in this study. The mRNA levels were found identical in variants containing exons IV and VI in cells examined. However, the mRNA level was different in variants containing the exon IX (Fig. 4). Statistical analysis proved that SK and LK2 cells expressed more BDNF variant IX than HBE, A549 and LTE cells (p = 0.000).

Suppression of cell proliferation by BDNF-shRNA
LK2 and A549 cells were transfected with specific shRNA to explore the function of BDNF on cell proliferation, apoptosis and invasion. Fig. 3b confirmed the decreased expression of BDNF in transfected cells. We found that 2 days after LK2 were seeded, and 3 days after A549 cells were seeded, the absorbance in BDNF-shRNA, scrambled and control groups was statistically different (p = 0.025 and p = 0.002). According to the cell growth curves during the 5 days, we found that both LK2 and A549 cells with BDNF-shRNA transfection showed a decreased proliferative activity compared with other groups. When retreated with rhBDNF, BDNF knockdown LK2 or A549 cells showed enhanced proliferative abilities (Fig. 5). These results showed that suppression of BDNF expression interfered with the proliferation of LK2 and A549 cells.

More apoptotic cells with BDNF-knockdown
Cell apoptosis was examined in this study to investigate whether BDNF facilitated overgrowth of cells by apoptosis inhibition. The apoptotic rates of LK2 cells in BDNF-shRNA, scrambled and control groups were 30.8 ± 1.9 %, 16.3 ± 2.7 % and 9.8 ± 1.6 % (p = 0.000; Fig. 6a, b, c). The apoptotic rates of A549 cells in the above groups were 21.7 ± 2.3 %, 9.1 ± 1.5 % and 4.1 ± 1.3 % (p = 0.000; Fig. 6e, f, g). When retreated with rhBDNF, the apoptotic LK2 or A549 cells with BDNF knockdown were apparently reduced (Fig. 6d and h). Our results showed that apoptosis was significantly induced in BDNF shRNA-transfected cells.

More apoptotic cells with BDNF-knockdown
Cell apoptosis was examined in this study to investigate whether BDNF facilitated overgrowth of cells by apoptosis inhibition. The apoptotic rates of LK2 cells in BDNF-shRNA, scrambled and control groups were 30.8 ± 1.9 %, 16.3 ± 2.7 % and 9.8 ± 1.6 % (p = 0.000; Fig. 6a, b, c). The apoptotic rates of A549 cells in the above groups were 21.7 ± 2.3 %, 9.1 ± 1.5 % and 4.1 ± 1.3 % (p = 0.000; Fig. 6e, f, g). When retreated with rhBDNF, the apoptotic LK2 or A549 cells with BDNF knockdown were apparently reduced (Fig. 6d and h). Our results showed that apoptosis was significantly induced in BDNF shRNA-transfected cells.
Down-regulation of BDNF on the invasive potential of shRNA-transfected cells

Since BDNF overexpression was common in more aggressive tumours, the stable cells of LK2 or A549 with low expression of BDNF were used to determine its contribution to cell invasion. The numbers of invasive LK2 or A549 cells in BDNF-shRNA or scrambled shRNA transfected and control groups were 31.3 ± 4.2, 72.0 ± 4.4, 65.7 ± 7.0 and 29.7 ± 4.2, 63.0 ± 7.2, 66.0 ± 7.2, respectively (p = 0.000; Fig. 7a-c and e-g). However, in the group of LK2 or A549 cells retreated with rhBDNF, chemotaxis of rhBDNF was shown as 45.7 ± 4.7 or 47.0 ± 5.6, which was both more than BDNF-shRNA group (p = 0.000; Fig. 7d and h). These results showed that BDNF knockdown significantly attenuated the invasive ability of transfected cells.

Discussion

Brain-derived neurotrophic factor, also known as BDNF, is a member of the “neurotrophin” family of growth factors, helping to support the survival of existing neurons, and encourage the growth and differentiation of new...
Fig. 6 The effects of BDNF knockdown or retreatment on cell apoptosis. The apoptotic rate of BDNF knockdown cells was evidently increased or decreased with rhBDNF treatment. a LK2 cells untreated. b scrambled shRNA transfected LK2 cells. c LK2 cells of BDNF knockdown. d LK2 cells with rhBDNF retreatment. e A549 cells untreated. f scrambled shRNA transfected A549 cells. g A549 cells of BDNF knockdown. h A549 cells with rhBDNF retreatment. The data are shown as mean ± SD of three individual experiments.

Fig. 7 The effects of BDNF knockdown or retreatment on cell invasion. a LK2 cells untreated. b scrambled shRNA transfected LK2 cells. c cell invasion was inhibited in BDNF-shRNA transfected LK2 cells. d more invasive cells were shown in rhBDNF treated BDNF-knockdown LK2 cells. e A549 cells untreated. f scrambled shRNA transfected A549 cells. g the number of invasive A549 cells with BDNF-shRNA transfection was reduced. h cells were more invasive after rhBDNF treatment. The values are mean ± SD of three independent experiments.
neurons and synapses [18]. The up-regulation of BDNF was found in a variety of primary human tumors, including breast cancer [19], hepatocellular carcinoma [20], and bladder cancer [21], suggesting a significant role of BDNF in the development and progression of cancer. The primary receptor for BDNF, TrkB is critical in lung cancer development. A recent study by Sinkevicius KW found that the receptor TrkB deficiency significantly reduced metastasis of a lung adenocarcinoma model [22]. Götz R also revealed that the cooperation of TrkB and EGFR signaling enhances migration and dispersal of lung tumor cells [23].

In this study, we evaluated the expression of BDNF in lung SCC and ADC. We found a statistical evidence of BDNF up-regulation in lung cancer, compared with their non-tumor counterparts. BDNF overexpression was found extensively in most of neoplastic tissues, supporting its potential role in lung tumorigenesis. We also examined 110 FFPE sections of lung SCC and ADC by means of immunohistochemistry to reveal the clinical significance of BDNF for lung cancer. We found that tumors with high BDNF expression had an advanced T stage, and SCC expressed more BDNF. It has been reported that the positive TrkB staining in SCC correlated specifically with improved disease-specific survival and overall survival [24]. Furthermore, the lineage transition in SCC and ADC of lung cancer was presumed for the clinical observation of mixed components in adenosquamous carcinoma recently. Studies have shown the evidence for the plasticity of lung cancer, that the transdifferentiation from SCC to ADC under implicated circumstances [25, 26]. However, the significance of BDNF in lung SCC still required intensive research. These results suggested that BDNF was critical in the tumorigenesis of lung cancer. Further studies and more samples are required to investigate the relationship between BDNF and TrkB in lung SCC and ADC.

It has been reported that BDNF is a secretory protein, produced by tumor cells to promote their growth and survival [27]. Therefore, BDNF in culture supernatant was assessed in HBE and four lung cancer cell lines. As we expected, the SCC cells of LK2 and SK had more secretion of BDNF in supernatant, compared to HBE and the ADC cells of A549 and LTE. We also examined the expression of BDNF by western blot in HBE and other lung cancer cells. We showed that BDNF expression represented by the specific protein band of 28 kDa was quite weak in HBE cells, while SK and LK2 cells expressed higher level of BDNF, compared with A549 and LTE cells. However, besides the specific BDNF bands, various protein bands were also found in cells, which were not present in tissue samples. We presumed that those unexpected bands were proteins probably containing its precursor proBDNF [28], or some unknown BDNF protein subtypes came from spliced mRNA variants, which requires further identifying and recognizing investigations.

It has been reported that 17 splice variants when BDNF gene was transcribed into mRNAs, and each variant is expressed in specific tissues and cells. Studies have shown that human BDNF alternative transcripts are expressed in a tissue-specific manner. According to the previous research, three BDNF mRNA transcripts containing exons IV, VI or IX, which are expressed relatively higher in lung tissue, were selected to be examined in this study to evaluate the significance of the above variants to the higher expression of BDNF in lung cancer cells. We found that the mRNA level of variants IV and VI was identical, only the mRNA level of variant IX was different among cells examined. SCC cells of SK and LK2 with more expression of BDNF protein had higher level of the mRNA variant IX. These results suggested that variant IX was responsible for the higher expression and secretion of BDNF protein, which was probably helpful to the development of SCC.

In this study, we explored the function of BDNF on proliferation, apoptosis and invasion by specific shRNA transfection in LK2 and A549 cells. It was confirmed that blocking of BDNF expression inhibited cell proliferation and invasion, and promoted cell apoptosis. Our data indicate that BDNF promotes cell proliferation and invasion, and silencing BDNF probably confers the disadvantage to the growth of lung cancer cells.

We have previously confirmed that TrkB was overexpressed in lung cancer, BDNF facilitated A549 cell invasion by inducing phosphorylation of Pyk2-tyr402, which is a newly found signaling associated with invasion of lung cancer cells. Pyk2 is also called Ca²⁺-dependent tyrosine kinase, which is involved in the regulation of Ca²⁺ flow-mediated signaling activations and cell migration. Therefore, the Ca²⁺/Pyk2 signaling involved in cell invasion were investigated recently. The LK2 and A549 cells with shBDNF transfection were stimulated by recombined human BDNF. We observed the elevated Ca²⁺ concentration and Pyk2-tyr402 phosphorylation, and cells invasion was also enhanced. Ca²⁺ concentration was significantly elevated after BDNF stimulation, and that was much lower in cells pretreated with endoplasmic reticulum Ca²⁺ channel protein IP3R blocker 2-APB than control cells, which indicated that BDNF promoted Ca²⁺ release from endoplasmic reticulum through IP3R. We are proposing to focus on Ca²⁺ signaling associated with invasion of lung cancer cells in our future studies.

Conclusion
In conclusion, our study demonstrated that overexpression of BDNF was evident in lung SCC and ADC, and the increased expression of BDNF protein in SCC cells was
closely correlated with higher level of its spliced mRNA variant containing exon IX. Knockdown of BDNF using RNA interfering showed the decreased activity of proliferation and invasion in LK2 and A549 cells, which indicated that BDNF may play a decisive role in tumorigenesis of lung SCC and ADC, whose growth and survival were probably facilitated by BDNF secreted by themselves. The suppression of BDNF may provide a significant target for inhibitory strategies for the development of lung cancer, which requires further investigations.

Abbreviations
ADC: adenocarcinoma; AMPK/ACC: Adenosine 5′-monophosphate (AMP)-activated protein kinase/acetyl-CoA carboxylase; BCA: bicinchoninic acid; BDNF: brain-derived neurotrophic factor; BSA: bovine serum albumin; CCK-8: cell counting kit; DAB: 3,3′-diaminobenzidine; ECL: enhanced chemiluminescence; ELISA: enzyme linked immunosorbent assay; ERK: extracellular signal-regulated kinase; FBS: fetal bovine serum; FPP: formalin-fixed paraffin-embedded; FITC: fluorescein isothiocyanate; H&E: human bronchial epithelial cell; HE: hematoxylin and eosin; IOD: integral optical density; IP3R: inositol 1,4,5-trisphosphate receptor; JAK/STAT: Janus kinase/signal transducer and activator of transcription; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; PBS: phosphate buffer saline; PI3K/AKT: phosphatidylinositol 3 kinase/protein kinase B; PLC/PKC: phospholipase C/protein kinase C; PVD: polyvinylidene fluoride; Pyk2: prolino-rich tyrosine kinase 2; rhBDNF: recombinant human BDNF; RIPA: radio-immunoprecipitation assay; SCC: squamous cell carcinoma; SD: standard deviation; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SP: streptavidin-peroxidase; SPSS: Statistical Product and Service Solutions; TrkB: tropomyosin-related receptor kinase B.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Sy Z initiated the research, carried out the experiments and wrote the manuscript. Lp H contributed to the paper translation, Cy L offered assistance with the experimental design, J G and Zs C gave experimental instructions, and Xs Q gave pertinent suggestions for the manuscript revision. All authors read and approved the final manuscript.

Acknowledgement
This study was supported by a grant from the National Natural Science Foundation of China (81101599) and the Science and Technology Funds of Shenyang (F12-264-4-01).

Author details
1Center of Laboratory Technology and Experimental Medicine, China Medical University, No.77 Puhe Road, Shenyang New North Area, Shenyang, Liaoning, People’s Republic of China. 2Laboratory Center, the Fourth Affiliated Hospital of China Medical University, No.4 Chongshang East Road, Huangguo District, Shenyang, Liaoning, People’s Republic of China. 3Department of Pathology, the First Affiliated Hospital of China Medical University, No.155 Nanjing North Street, Hepeing District, Shenyang, Liaoning, People’s Republic of China.

Received: 20 September 2015 Accepted: 24 February 2016

Published online: 29 February 2016

References
1. Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci. 2006;63(13):1523–37.
2. Sandhya VK, Raju R, Verma R, Advani J, Sharma R, Radhakrishnan A, et al. A network map of BDNF/TrkB and BDNF/p75NTR signaling system. J Cell Commun Signal. 2013;7(4):301–7.
3. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varella CR, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2000;15(10):3244–50.
4. Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Betteaux N, et al. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 2011;17(7):1741–52.
5. Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, et al. Role and relevance of TrKB mutations and expression in non-small lung cell cancer. Clin Cancer Res. 2011;17(9):2638–45.
6. Liu M, Su YH, Chen Y. Expressions of neurotrophic factors and their receptors in prostate cancer. Zhonghua Nan Ke Xue. 2010;16(2):129–31.
7. Yang X, Martin TA, Jiang WG. Biological influence of brain-derived neurotrophic factor (BDNF) on colon cancer cells. Exp Ther Med. 2013;6(6):1475–81.
8. Sun CY, Hu Y, Huang J, Chu ZB, Zhang L, She XM, et al. Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol. 2010;31(2):1211–8.
9. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010;29(14):2047–59.
10. Guo D, Sun W, Zhu L, Zhang H, Hou X, Liang J, et al. Knockdown of BDNF suppressed invasion of HepG2 and HCCLM3 cells, a mechanism associated with inactivation of RhoA or Rac1 and actin skeleton disorganization. APMIS. 2012;120(6):469–76.
11. Huang YT, Lai PC, Wu CC, Cheng CC, Chiu TH. TrkB antibody elicits cytotoxicity and suppresses migration/invasion of transitional cell carcinoma cells. Int J Oncol. 2010;37(4):943–9.
12. Ricci A, Greco S, Marliotta S, Felici L, Bronzetti E, Cavazzana A, et al. Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol. 2001;25(4):439–49.
13. Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, Koga T, et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;78(1):100–6.
14. Odate S, Nakamura K, Onishi H, Kojima M, Uchiyama A, Nakano K, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79(3):205–14.
15. Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, et al. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer. 2010;10:443.
16. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human neurotrophic factor. Lancet. 2010;376(9737):320–7.
17. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79(3):205–14.
18. Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, et al. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer. 2010;10:443.
19. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human neurotrophic factor. Lancet. 2010;376(9737):320–7.
20. Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, Koga T, et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;78(1):100–6.
21. Patani N, Jiang WG, Mokbel K. Brain-derived neurotrophic factor expression predicts adverse pathological & clinical outcomes in human breast cancer. Cancer Cell Int. 2011;11(12).
22. Guo D, Hou X, Zhang H, Sun W, Zhu L, Liang J, et al. More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, suppressed invasion of HepG2 and HCCLM3 cells. J Exp Clin Cancer Res. 2011;30:97.
23. Lai PC, Chiu TH, Huang YT. Overtexpression of BDNF and TrkB in human bladder cancer specimens. Oncol Rep. 2010;24(5):1265–70.
24. Sinkevicius KW, Kriegel C, Bellaria KJ, Lee J, Lau AN, Leeman KT, et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Nat Acad Sci U S A. 2014;111(12):299–304.
25. Götz R, Sendtner M. Cooperation of tyrosine kinase receptor TrkB and epidermal growth factor receptor signaling enhances migration and dispersal of lung tumor cells. PLoS One. 2014;9(6), e100944.
26. Jerry J, De Luca A, Leung S, Peacock G, Wang Y, Elliot WM, et al. Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes. Arch Pathol Lab Med. 2011;135(4):433–9.
27. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2010;70(5):3261–7.
28. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun. 2014;5:4629.
27. Akil H, Perraud A, Mélin C, Jauberteau MO, Mathonnet M. Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One. 2011;6(9), e25097.

28. Je HS, Yang F, Ji Y, Nagappan G, Hempstead BL, Lu B. Role of pro-brain-derived neurotrophic factor (proBDNF) to mature BDNF conversion in activity-dependent competition at developing neuromuscular synapses. Proc Natl Acad Sci U S A. 2012;109(39):15924–9.